Troglitazone: The discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus

Advanced Drug Delivery Reviews

Volumn 54, Issue 9, 2002, Pages 1173-1197

  Parker, Janice C ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antidiabetic; Glitazone; Glucose tolerance; Glycemia; Insulin resistance; Insulin sensitizer; Thiazolidinedione

Indexed keywords

BLOOD; CARDIOLOGY; GLUCOSE; INSULIN;

SENSITIZING AGENTS;

DRUG THERAPY;

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; ACARBOSE; ADD 4833; CIGLITAZONE; DARGLITAZONE; ENGLITAZONE; ESTRADIOL; ESTRONE; FARGLITAZAR; FATTY ACID; FRUCTOSAMINE; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; GW 0072; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; ISAGLITAZONE; L 764406; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENFORMIN; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGLITAZAR; REPAGLINIDE; ROSIGLITAZONE; SB 213068; SULFONYLUREA DERIVATIVE; TESTOSTERONE; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOGLIBOSE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; THIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ATHEROGENESIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DYSLIPIDEMIA; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIVER TOXICITY; MOLECULAR MECHANICS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

CHROMANS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0037027301     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00093-5     Document Type: Article

References (181)

1. Eschwege E., Simon D., Balkau B. The growing burden of diabetes in the world population. IDF Bull. 42:1997;14-19.
2. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetologia. 35:1992;389-397.
3. Nijpels G. Determinants for the progression from impaired glucose tolerance to non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 28:(Suppl. 2):1998;8-13.
4. DCCT . The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New Engl. J. Med. 329:1993;977-986.
5. Nathan D.M. Inferences and implications. Do results from the Diabetes Control and Complications Trial apply in NIDDM? Diabetes Care. 18:1995;251-257.
6. UKPDS . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (United Kingdom Prospective Diabetes Study 33). Lancet. 352:1998;837-853.
7. UKPDS . Effect of intensive blood glucose control with metformin on complications in overweight patients with Type 2 diabetes (United Kingdom Prospective Diabetes Study 34). Lancet. 352:1998;854-865.
8. UKPDS . A 6-year, randomized, controlled trial comparing sulfonylurea, insulin and metformin therapy (United Kingdom Prospective Diabetes Study 24). Ann. Int. Med. 128:1998;165-175.
9. DeFronzo R.A., Ferrannini E., Simonson D.C. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 38:1989;387-395.
10. Porte D. Jr. β-Cells in type II diabetes mellitus. Diabetes. 40:1991;166-180.
11. Gerich J.E. Oral hypoglycemic agents. New Engl. J. Med. 321:1989;1231-1245.
12. Goldman J.M. Oral hypoglycemic agents: an update of sulfonylureas. Drugs Today. 25:1989;689-695.
13. DeFronzo R.A. Pharmacological therapy for Type 2 diabetes. Ann. Intern. Med. 131:1999;281-303.
14. Groop L.C. Sulfonylureas in NIDDM. Diabetes Care. 15:1992;737-754.
15. Wright A., Burden A.C., Paisley R.B., Cull C.A., Holman R.R. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK (United Kingdom prospective Diabetes Study 57). Diabetes Care. 25:2002;330-336.
16. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over 6 years. UK Prospective Diabetes Study (UKPDS) Group. Diabet. Med. 15:1998;297-303.
17. Nattrass M., Alberti K.G.M. Biguanides. Diabetologia. 14:1978;71-74.
18. Cusi K., DeFronzo R.A. Metformin. A review of its metabolic effects. Diabetes Rev. 6:1998;89-131.
19. Misbin R.I., Green L., Stadel B.V. Lactic acidosis in patients with diabetes treated with metformin. New Engl. J. Med. 338:1998;265-266.
20. DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. New Engl. J. Med. 333:1995;541-549.
21. Garber A.J., Duncan T.G., Goodman A.M., Mills D.J., Rohlf J.L. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am. J. Med. 103:1997;491-497.
22. Bailey C.J. Biguanides and NIDDM. Diabetes Care. 15:1992;755-772.
23. Bailey C.J., Turner R.C. Metformin. New Engl. J. Med. 334:1996;574-579.
24. Wollen N., Bailey C.J. Inhibition of hepatic gluconeogenesis by metformin. Biochem. Pharmacol. 37:1988;4353-4358.
25. DeFronzo R.A., Barzilai N., Simonson D.C. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J. Clin. Endocrinol. Metab. 73:1991;1294-1301.
26. Stumvoll N., Nurjhan N., Perriello G., Dailey G., Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. New Engl. J. Med. 333:1995;550-554.
27. Hundal R.S., Krssak M., Dufour S., Laurent D., Lebon V., Chandramouti V., Inzucchi S.E., Schumann W.C., Petersen K.F., Landau B.R., Schulman G.I. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 49:2000;2063-2069.
28. Coniff R.F., Shapiro J.A., Seaton T.B. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch. Intern. Med. 154:1994;2442-2448.
29. Lebovitz H.E. A new oral therapy for diabetes management: α-glucosidase inhibition with acarbose. Clin. Diabetes. 13:1995;99-103.
30. Campbell L.K., White J.R., Campbell R.K. Acarbose: Its role in the treatment of diabetes mellitus. Ann. Pharmacother. 30:1996;1255-1262.
31. Chiasson J.L., Josse R.G., Hunt J.A., Palmason C., Rodger N.W., Ross S.A., Ryan E.A., Wolever T.M. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann. Intern. Med. 121:1994;928-935.
32. UKPDS . A randomized trial of efficacy of metformin in sulfonylurea-treated type 2 diabetes (United Kingdom Prospective Diabetes Study 28). Diabetes Care. 21:1998;87-92.
33. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (United Kingdom Prospective Diabetes Study 49). J. Am. Med. Assoc. 281:1999;2005-2012.
34. Sohda T., Mizuno K., Imamiya E., Sugiyama Y., Fukits T., Kawamatsu Y. Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]-thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem. Pharm. Bull. 30:1982;3580-3600.
35. Kawamatsu Y., Saraie T., Imamiya E., Nishikawa K., Hamuro Y. Studies on antihyperlipidemic agents. I. Synthesis and hypolipidemic activities of phenoxylphenyl alkanoic acid derivatives. Arzneim. Forsch./Drug Res. 30:1980;454-459.
36. Fujita T., Sugiyama Y., Taketomi S., Shoda T., Kawamatsu Y., Iwatsuka H., Suzuoki Z. Reduction of insulin resistance on obese and/or diabetic animals by 3[-4(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3870, U-63287, ciglitazone) a new antidiabetic agent. Diabetes. 32:1983;804-810.
37. Feingold K.R., Grunfeld C., Pang M., Doerrler W., Krauss R.M. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler. Thromb. Vasc. Biol. 12:1992;1496-1502.
38. Laakso M., Lehto S., Penttilä I., Pyörälä K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 88:1993;1421-1430.
39. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witzum J.L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. New Engl. J. Med. 320:1989;915-924.
40. Witzum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1991;1785-1792.
41. Esterbauer H., Dieber-Rotheneder M., Puhl H., Tatzber F. Endogenous antioxidants and lipoprotein oxidation. Biochem. Soc. Trans. 18:1990;1059-1061.
42. Jialal I., Fuller C.J., Huet B.A. The effect of α-tocopherol supplementation on LDL oxidation: a dose-response study. Arterioscler. Thromb. Vasc. Biol. 15:1995;190-198.
43. Tack C.J., Smits P., Demacker P.N., Stalenhoef A.F. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 21:1998;796-799.
44. Cominacini L., Young M.M., Capriati A., Garbin U., Fratta Pasini A., Campagnola M., Cavoli A., Gigoni A., Contessi G.B., Lo Cascio V. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia. 40:1997;1211-1218.
45. Cominacini L., Garbin U., Fratta Pasini A., Campagnola M., Davoli A., Foot E., Sighieri G., Sironi A., Lo Cascio V., Ferrannini E. Troglitazone reduces LDL oxidation and lowers plasma E-selectin in NIDDM patients. Diabetes. 47:1998;130-133.
46. Fujiwara T., Yoshioka S., Yoshioka Y., Ushiyama I., Horokishi H. Characterization of new oral antidiabetic agent CS-045. Diabetes. 37:1988;1549-1558.
47. Lee M.K., Miles P.D.G., Khoursheed M., Gao K.M., Mossa A.R., Olefsky J.M. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes. 43:1994;1435-1439.
48. Fujiwara T., Wade T., Fukuda K., Fukami M., Yoshioko S., Yoshioko T., Horoikoshi H. Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KSJ- db/db mice. Metabolism. 40:1991;1213-1218.
49. Khoursheed M., Miles P.D.G., Gao K.M., Lee M.K., Mossa A.R., Olefsky J.M. Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism. 44:1995;1489-1494.
50. Tominaga M., Igarashi M., Daimon M., Eguchi H., Matsumoto M., Sekikawa A., Yamatomi K., Sasaki H. Thiazolidinediones (AD-4533 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocrin. J. 40:1993;343-349.
51. Stevenson R.W., McPherson R.K., Genereux P.E., Danbury B.H., Kreutter D.K. Antidiabetic agent englitazone enhances insulin action in nondiabetic rats without producing hypoglycemia. Metabolism. 40:1991;1268-1274.
52. Bowen L., Steven P.P., Stevenson R.W., Shulman G.I. The effect of CP-68722, a thiazolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats. Metabolism. 40:1991;1025-1030.
53. Oakes N.D., Kennedy C.J., Jenkins A.B., Laybulf D.R., Chisholm D.J., Kraegen E.W. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes. 43:1994;1203-1210.
54. Fujiwara T., Okuno A., Yoshioka S., Horikoshi H. Suppression of hepatic gluconeogenesis in chronic troglitazone (CS-045)-treated diabetic KK and C57BL/KSJ- db/db mice. Metabolism. 44:1995;486-490.
55. Stevenson R.W., Gibbs E.M., Kreutter D.K., McPherson R.K., Clark D.A., Hulin B., Goldstein S.W., Parker J.C., Swick A.G., Treadway J.L., Hargrove D.M., Shulman G.I. The thiazolidine drug series. Marshall S.M., Home P.D., Rizza R.A., The Diabetes Annual. Vol. 9:1995;175-191 Elsevier, Amsterdam.
56. Whitcomb R.W., Saltiel A.R. Thiazolidinediones. Exp. Opin. Invest. Drugs. 4:1995;1299-1309.
57. Hoffman C., Lorenz K., Colca J.R. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology. 129:1991;1915-1925.
58. Sugiyama Y., Shimura Y., Ikeda H. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim. Forsch./Drug Res. 40:1990;436-440.
59. Sreenan S., Sturis J., Pugh W., Burant C.F., Polonsky K.S. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin and troglitazone. Am. J. Physiol. 241:1996;E742-747.
60. Young M.A., Lettis S., Eastmond R. Improvement in the gastrointestinal absorption of troglitazone when taken with, or shortly after, food. Br. J. Clin. Pharmacol. 45:1998;31-35.
61. Loi C.M., Young M., Randinitis E., Vassos A., Koup J.R. Clinical pharamockinetics of troglitazone. Clin. Pharmacokinet. 37:1999;91-104.
62. Loi C.M., Randinitis E.J., Vassos A.B., Kazierad D.J., Koup J.R., Sedman A.J. Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study. J. Clin. Pharmacol. 37:1997;1114-1120.
63. Young M.A., Donoghue S., Williams Z.V., Eastmond R. Similar pharmacokinetics of troglitazone in young and elderly. 32nd Annual Meeting of the European Association for the Study of Diabetes (1996); Vienna, Austria:1996.
64. Shibukawa A., Sawada T., Nakao C., Izumi T., Nakagawa T. High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and human plasma. J. Chromatogr. A. 697:1995;337-343.
65. Izumi T., Enomoto S., Hosiyama K., Sasahara K., Shibukawa A., Nakagawa T., Sugiyama Y. Prediction of the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J. Pharmacol. Exp. Ther. 277:1996;1630-1641.
66. Kawai K., Kawasaki-Tokui Y., Odaka T., Tsuruta F., Kazui M., Iwabuchi H., Nakamura T., Kinoshita T., Ikeda T., Yoshioka T., Komai T., Nakamura K. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneim. Forsch./Drug Res. 47:1997;356-358.
67. Loi C.M., Alvey C.W., Randinitis E.J., Abel R., Young M.A., Koup J.R. Meta-analysis of steady-state pharmacokinetics of troglitazone and its metabolites. J. Clin. Pharmacol. 37:1997;1038-1047.
68. Iwamoto Y., Kuzuya T., Matsuda A., Awata T., Kumakura S., Inooka G., Shiraishi I. Effect of new oral anti-diabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 14:1991;1083-1086.
69. Onuma T., Tsutsi M., Goto T., Boku A., Takebe K. The effect of a new oral hypoglycemic drug, CS-045, on glucose tolerance and serum lipids in non-obese Japanese patients with non-insulin dependent diabetes mellitus: a pilot study. Curr. Ther. Res. 55:1994;416-421.
70. Mimura K., Umeda F., Hiramatsu S., Taniguchi S., Ono Y., Nakashima N., Kobayashi K., Masakado M., Sako Y., Nawata H. Effects of a new oral hypoglycemic agent (CS-045) on metabolic abnormalities and insulin resistance in Type 2 diabetes. Diabet. Med. 11:1994;685-691.
71. Sironi A., Vihi S., Gastadelli A., Anichini R., Garbin U., Cominacini L., Seghieri G., Ferrannini E. Effects of troglitazone on insulin sensitivity and cardiovascular risk factors (CVRF) in NIDDM. Diabetes. 45:(Suppl. 2):1996;185A.
72. Sironi A., Vichi S., Gastadelli A., Pecori N., Anichini R., Foot E., Seghieri G., Ferrannini E. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin. Pharmacol. Ther. 62:1997;194-202.
73. Kuzuya T., Iwamoto Y., Kosaka K., Takebe K., Yamanouchi T., Kasuga M., Kajinuma H., Akanuma Y., Yoshida S., Shigeta Y., Baba S. A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res. Clin. Pract. 11:1991;147-153.
74. Suter S.L., Nolan J.J., Wallace P., Gumbiner B., Olefsky J.M. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care. 15:1992;193-194.
75. Iwamoto Y., Kozaka K., Kuzuya T., Akanuma Y., Shigeta Y., Kaneko T. Effects of troglitazone. A new hypoglycemic agent in patients with NIDDM poorly controlled with diet therapy. Diabetes Care. 19:1996;151-156.
76. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., Olefsky J.M. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. New Engl. J. Med. 331:1994;1188-1193.
77. Grossman S.L., Lessem J. Mechanisms and clinical effects of thiazolidinediones. Exp. Opin. Invest. Drugs. 6:1997;1025-1040.
78. Spiegelman B.M. PPARγ: adipogenic regulator and thiazolidinedione receptor. Diabetes. 47:1998;507-514.
79. Kumar S., Boulton H.J.M., Beck-Nielsen H., Berthezene F., Muggeo M., Persson B., Spinas G.A., Donoghue S., Lettis S., Stewart-Long P. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 39:1996;701-709.
80. Fonseca V.A., Valiquett T.R., Huang S.M., Ghazzi M.N., Whitcomb R.W. Troglitazone monotherapy improves glycemic control in patients with Type 2 diabetes mellitus: a randomized, controlled study. J. Clin. Endocrinol. Metab. 83:1998;3169-3176.
81. Maggs D.G., Buchanan T.A., Burant C.F., Cline G., Gumbiner B., Hseuh W.A., Inzucchi S., Kelley D., Nolan J., Olefsky J.M., Polonsky K.S., Silver D., Valiquett T.R., Shulman G.I. Metabolic effects of troglitazone monotherapy in Type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 128:1998;176-185.
82. Schwartz S., Raskin P., Fonesca V.A., Graveline J.F. Effect of troglitazone in Insulin-treated patients with Type II diabetes mellitus. New Engl. J. Med. 338:1998;861-866.
83. Buse J.B., Gumbiner B., Mathias N.P., M N.D., Faja B.W., Whitcomb R.W. Troglitazone use in insulin-treated Type 2 diabetic patients. Diabetes Care. 21:1998;1455-1461.
84. Horton E.S., Whitehouse F., Ghazzi M.N., Venable T.C., Whitcomb R.W. Troglitazone in combination with sulfonylurea restores glycemic control in patients with Type 2 diabetes. Diabetes Care. 21:1998;1462-1469.
85. Fonseca V.A., Foyt H.L., Shen K., Whitcomb R. Long-term effects of troglitazone. Open label extension studies in Type 2 diabetic patients. Diabetes Care. 23:2000;354-359.
86. Iwamoto Y., Kosaka K., Kuzuya T., Akanuma Y., Shigeta Y., Kaneko T. Effect of combination therapy of troglitazone and sulfonylureas in patients with Type 2 diabetes who were poorly controlled by sulfonylurea therapy alone. Diabet. Med. 13:1996;365-370.
87. Buysschaert M., Bobboni E., Starkie M., Frith L. Troglitazone in combination with sulphonylurea improves glycaemic control in Type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Diabet. Med. 16:1999;147-153.
88. Inzucchi S.E., Maggs D.G., Spollett G.R., Page S.I., Rife F.S., Walton V., Shulman G.I. Efficacy and metabolic effects of metformin and troglitazone in Type II diabetes mellitus. New Engl. J. Med. 338:1998;867-872.
89. Yale J.-F., Valiquett T.R., Ghazzi M.N., Owens-Grillo J.K., Whitcomb R.W., Foyt H.L. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with Type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. Ann. Intern. Med. 134:2001;737-745.
90. Raskin P., Jovanovic L., Berger S., Schwartz S., Woo V., Ratner R. Repaglinide/troglitazone combination therapy. Diabetes Care. 23:2000;979-983.
91. Bando Y., Ushiogi Y., Okafuji K., Toya D., Tanaka N., Fujisawa M. Troglitazone combination therapy in obese Type 2 diabetic patients poorly controlled with α-glucosidase inhibitors. J. Int. Med. Res. 27:1999;53-64.
92. Betteridge D.J. Diabetic dyslipidemia. Diabetes Obesity Metab. 2:(Suppl. 1):2000;S31-36.
93. Timar O., Sestier F., Levy E. Metabolic syndrome X: a review. Can. J. Cardiol. 16:2000;779-789.
94. Austin M.A. Plasma triglyceride as a risk factor for coronary heart disease: the epidemiological evidence and beyond. Am. J. Epidemiol. 129:1989;249-259.
95. Ghazzi M.N., Perez J.E., Antonucci T., Driscoll J.H., Huang S.M., Faja B.W., Whitcomb R.W. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 46:1997;433-439.
96. Antonucci T., Whitcomb R.W., McLain R., Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care. 20:1997;188-193.
97. Sunayama S., Watanabe Y., Ohmura H., Sawano M., Shimada K., Mokuno H., Daida H., Yamaguchi H. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis. 146:1999;187-193.
98. Yoshioka S., Nishino H., Shiraki T., Ikeda K., Koike H., Okuno A., Wada M., Fujiwara T., Horokoshi H. Metabolism. 42:1993;75-80.
99. Burant C.F., Sreenan S., Hirano K., Tai T.A., Lohmiller J., Likens J., Davidson N.O., Ross S.A., Graves R.A. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100:1997;2900-2908.
100. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607.
101. Rosenstock J., Raskin P. Hypertension in diabetes mellitus. Cardiol. Clin. 6:1988;547-560.
102. Simonson D.C. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care. 11:1988;821-827.
103. Bonora E., Kiechl S., Willeit J., Oberhollenzer F., Egger G., Targher G., Alberiche M., Bonadonna R.C., Muggeo M. Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes. 47:1998;1643-1649.
104. UKPDS . Tight blood pressure control and the risk of microvascular and macrovascular complications in Type 2 diabetes (United Kingdom Prospective Diabetes Study 38). Br. Med. J. 317:1998;703-713.
105. Ogihara T., Rakugi H., Ikegami H., Mikami H., Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am. J. Hypertens. 8:1995;316-320.
106. Tack C.J., Ong M.K.E., Lutterman J.A., Smits P. Insulin-induced vasodilation and endothelial function in obesity/insulin-resistance: effects of troglitazone. Diabetologia. 41:1998;569-576.
107. 2+ channels in smooth muscle cells from resistance arteries of guinea-pig. Br. J. Pharmacol. 123:1998;675-682.
108. Driscoll J., Ghazzi M., Perez J., Huang S., Whitcomb R. A 96-week follow-up on cardiac safety in patients with Type 2 diabetes treated with troglitazone. Diabetes. 46:(Suppl. 1):1997;149A.
109. Murakami T., Mizuno S., Ohsato K., Moriuchi I., Arai Y., Nio Y., Kaku B., Takahashi Y., Ohnaka M. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am. J. Cardiol. 84:1999;92-94.
110. Watanabe Y., Sunayama S., Shimada K., Sawano M., Hoshi S., Iwama Y., Mokuno H., Daida H., Yamaguchi H. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J. Atheroscler. Thromb. 7:2000;159-163.
111. Potter van Loon B.J., Kluft C., Radder J.K., Blankenstein M.A., Meinders A.E. The cardiovascular risk factor plasminogen activator inhibitor Type 1 is related to insulin resistance. Metabolism. 42:1993;945-949.
112. Alessi M.C., Peiretti F., Morange P., Henry M., Nalbone G., Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes. 46:1997;860-867.
113. Fonseca V.A., Reynolds T., Hemphill D., Randolph C., Wall J., Valiquett T.R. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J. Diabetes Comp. 12:1998;181-186.
114. Kruszynska Y.T., Yu J.T., Olefsky J.M., Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with Type 2 diabetes and in lean and obese normal subjects. Diabetes. 49:2000;633-639.
115. Ehrmann D.A., Scheneider D.J., Sobel B.E., Cavaghan M.K., Imperial J., Rosenfield R.L., Polonsky K.S. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82:1997;2108-2116.
116. Ishizuka M., Itazya S., Wada H., Ishizawa M., Kimura M., Kajita K., Kanoh Y., Miura A., Muto N., Yasuda K. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes. 47:1998;1494-1500.
117. Howard G., O'Leary D.H., Zaccaro D. Insulin sensitivity and atherosclerosis. Circulation. 93:1996;1809-1817.
118. Minamikawa J., Tanaka S., Yamauchi M., Inoue D., Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 83:1998;1818-1820.
119. Takagi T., Yoshida K., Akasaka T. Troglitazone reduces intimal hyperplasia after coronary stent implantation in patients with type 2 diabetes mellitus: a serial intravascular ultrasound study. J. Am. Coll. Cardiol. 33:(Suppl. A):1999;100A.
120. Takagi T., Akasaka T., Yamamuro A., Honda Y., Hozumi T., Morioka S., Yoshida K. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J. Am. Coll. Cardiol. 36:2000;1529-1535.
121. Franks S. Polycystic ovary syndrome. New Engl. J. Med. 333:1995;853-861.
122. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 81:1996;3299-3306.
123. Azziz R., Ehrmann D., Legro R.S., Whitcomb R.W., Hanley R., Fereshetian A.G., O'Keefe M., Ghazzi M.N. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 86:2001;1626-1632.
124. Ehrmann D.A., Cavaghan M.K., Imperial J., Sturis J., Rosenfield R.L., Polonsky K.S. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82:1997;524-530.
125. Masuda K., Okamoto Y., Tsuura Y., Kato S., Miura T., Tsuda K., Horokoshi H., Ishida H., Seino Y. Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia. 38:1995;24-30.
126. Ohtani K., Shimizu H., Sato N., Mori M. Troglitazone (CS-045) inhibits β-cell proliferation rate following stimulation of insulin secretion in HIT-T 15 cells. Endocrinology. 139:1995;172-178.
127. Cavaghan M.K., Ehrmann D.A., Byrne M.M., Polonsky K.S. Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J. Clin. Invest. 100:1997;530-537.
128. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Berkowitz K., Marroquin A., Goico J., Ochoa C., Azen S.P. Response of pancreatic β-cells to improved insulin sensitivity in women at high risk for Type 2 diabetes. Diabetes. 49:2000;782-788.
129. Prigeon R.L., Kahn S.E., Porte D. Effect of troglitazone on β cell function, insulin sensitivity and glycemic control in subjects with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 83:1998;819-823.
130. Shimabukuro M., Zhou Y.T., Lee Y., Unger R.H. Troglitazone lowers islet fat and restores β-cell function of Zucker Diabetic Fatty rats. J. Biol. Chem. 273:1998;3547-3550.
131. Higa M., Zhou Y.T., Ravazzola M., Baetens D., Orci L., Unger R.H. Troglitazone prevents mitochondrial alterations, β cell destruction and diabetes in obese prediabetic rats. Proc. Natl. Acad. Sci. USA. 96:1999;11513-11518.
132. Azen S.P., Peters R.K., Berkowitz K., Kjos S.L., Xiang A., Buchanan T.A. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control. Clin. Trials. 19:1998;217-231.
133. Berkowitz K., Peters R.K., Kjos S.L., Goico J., Marroquin A., Dunn M.E., Xiang A., Azen S., Buchanan T.A. Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes. 45:1996;1572-1579.
134. Buchanan T.A. 37th Annual Meeting of the European Association for the Study of Diabetes (2001); Glasgow, UK:2001.
135. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., Ochoa C., Tan S., Azen S.P. Protection from Type 2 diabetes persists in the TRIPOD cohort 8 months after stopping troglitazone. Diabetes. 50:(Suppl. 1):2001;A81.
136. Johnson M.D., Campbell L.K., Campbell R.K. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann. Pharmacother. 32:1998;337-348.
137. Mayfield R., McLean D., Crook D., Buist D.P., Gopinath C. CS-045 toxicity to the cynomolgus monkeys by repeated oral administration for 52 weeks. J. Clin. Ther. Med. 9:(Suppl. 3):1993;317-341.
138. Watkins P.B., Whitcomb R.W. Hepatic dysfunction associated with troglitazone. New Engl. J. Med. 338:1998;916-917.
139. Anonymous, Liver damage warnings for troglitazone, Scrip 2282 (1997) 21.
140. Gitlin N., Julie N.L., Spur C.L., Lom K.L., Juarbe H.M. Two cases of severe clinical and histological hepatotoxicity associated with troglitazone. Ann. Int. Med. 129:1998;36-38.
141. Neuschwander-Tetri B.A., Isley W.L., Oki J.C., Ramrakhiani S., Quiason S.G., Phillips N.J., Brunt E.M. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann. Int. Med. 129:1998;38-41.
142. Vella A., de Groen P.C., Dinneen S.F. Fatal hepatotoxicity associated with troglitazone. Ann. Intern. Med. 129:1998;1080.
143. Shibuya A., Watanabe M., Fujita Y. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care. 21:1998;2140-2143.
144. Scheen A.J. Thiazolidinediones and liver toxicity. Diabetes Metab. 27:2001;305-313.
145. Ibrahimi A., Teboul L., Gaillard D., Amri E., Ailhaud G., Young P., Cawthorne M., Grimaldi P. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. 46:1994;1070-1076.
146. Kletzien R.F., Foellmi L.A., Harris P.K., Wyse B.M., Clarke S.D. Adipocyte fatty acid-binding protein: regulation of gene expression in vivo and in vitro by an insulin-sensitizing agent. Mol. Pharmacol. 42:1992;558-562.
147. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. mPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1994;1224-1234.
148. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:1995;12953-12956.
149. Berger J., Bailey P., Biswas C., Cullinan C.A., Doebber T.W., Hayes N.S., Saperstein R., Smith R.G., Leibowitz M.D. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 137:1996;4189-4195.
150. Willson T.M., Cobb J.E., Cowan D.J., Wiethe R.W., Correa I.D., Prakash S.R., Beck K.D., Moore L.B., Kliewer S.A., Lehmann J.M. The structure-activity relationship between PPARγ agonism and the anti-hyperglycemic activity of thiazolidinediones. J. Med. Chem. 39:1996;665-668.
151. Ciaraldi T.P., Gilmore A., Olefsky J.M. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism. 39:1990;1056-1062.
152. Peraldi P., Xu M., Spiegelman B.M. Thiazolidinediones block TNF-α induced inhibition of insulin signaling. J. Clin. Invest. 100:1997;1863-1869.
153. Miles P.D.G., Romeo O.M., Higo K., Cohen A., Rafaat K., Olefsky J.M. TNF-α-induced insulin resistance and its prevention by troglitazone. Diabetes. 46:1997;1678-1683.
154. Kallen C.B., Lazar M.A. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc. Natl. Acad. Sci. USA. 93:1996;5793-5796.
155. Mokuda O., Sakamoto Y. Troglitazone reduces free fatty acid-induced insulin resistance in perfused rat hindquarter. Diabetes Metab. 24:1998;362-364.
156. Ranganathan S., Kern P.A. Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes. J. Biol. Chem. 273:1998;26117-26122.
157. Bergman R.N., Ader M. Free fatty acids and the pathogenesis of type 2 diabetes mellitus. Trends Endocrinol. Metab. 11:2000;351-356.
158. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
159. 12,14 prostaglandin J2 is a ligand for PPARγ Cell. 83:1995;803-812.
160. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proc. Natl. Acad. Sci. USA. 94:1997;4318-4323.
161. Brown K.K., Henke B.R., Blanchard S.G., Cobb J.E., Mook R., Kaldor I., Kliewer S.A., Lehmann J.M., Lenhard J.M., Harrington W.W., Novak P.J., Faison W., Binz J.G., Hashim M.A., Oliver W.O., Brown H.R., Parks D.J., Plunket K.D., Tong W.-Q., Menius J.A., Adkison K., Noble S.A., Willson T.M. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 48:1999;1415-1424.
162. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ Nature. 395:1998;137-143.
163. Walker A.B., Naderali E.K., Chattington P.D., Buckingham R.E., Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes. 47:1998;810-814.
164. Camp H.S., Li O., Wise S.C., Hong Y.H., Frankowski C.L., Shen X., Vanbogelen R., Leff T. Differential activation of peroxisome
165. McDonnell D.P. The molecular pharmacology of SERMs. Trends Endocrinol. Metab. 10:1999;301-311.
166. Olefsky J.M., Saltiel A.R. PPARγ and the treatment of insulin resistance. Trends Endocrinol. Metab. 11:2000;362-368.
167. Moller D.E., Greene D.A. Peroxisome proliferator-activated receptor (PPAR)γ agonists for diabetes. Adv. Protein Chem. 56:2001;181-212.
168. Sood V., Coleran K., Burge M.R. Thiazolidinediones: a comparative review of approved uses. Diabetes Tech. Ther. 2:2000;429-440.
169. Schoonjans K., Auwerx J. Thiazolidinediones: an update. Lancet. 355:2000;1008-1110.
170. Guerre-Millo M., Gervois P., Raspe E., Madsen L., Poulain P., Derudas B., Herbert J.M., Winegar D.A., Willson T.M., Fruchart J.C., Berge R.K., Staels B. Peroxisomal proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275:2000;16638-16642.
171. Ikeda H., Taketomi S., Sugiyama Y., Shimura Y., Sohda T., Meguro K., Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzeneim. Forsch./Drug Res. 40:1990;156-162.
172. Stevenson R.W., Hutson N.J., Krupp M.N., Volkmann R.A., Holland G.F., Eggler J.F., Clark D.A., McPherson R.K., Hall K.L., Danbury B.H. Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice. Diabetes. 39:1990;1218-1227.
173. Zhang B., Szalkowski D., Diaz E., Hayes N., Smith R., Berger J. Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes. J. Biol. Chem. 269:1994;25735-25741.
174. Cantello B.C.C., Cawthorne M.A., Cottam G.P., Duff P.T., Haigh D., Hindley R.M., Lister C.A., Smith S.A., Thurlby P.L. [[Ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem. 37:1994;3977-3985.
175. Liu L.S., Tanaka H., Ishii S., Eckel J. The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Endocrinology. 139:1998;4531-4539.
176. Murakami K., Tobe K., Ide T., Mochizuki T., Ohashi M., Akanuma Y., Yazaki Y., Kadowaki T. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ: effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes. 47:1998;1841-1847.
177. Henke B.R., Blanchard S.G., Brackeen M.F., Brown K.K., Cobb J.E., Collins J.L., Harrington W.W., Hashim M.A., Hull-Ryde E.A., Kaldor I., Kliewer S.A., Lake S.A., Leesnitzer L.M., Lehmann J.M., Lenhard J.M., Orband-Miller L.A., Miller J.F., Mook R.A., Nobel S.A., Oliver W., Parks D.J., Plunket K.D., Szewczyk J.R., Willson T.M. N-(2-Benzoylphenyl)-L-tyrosine PPARγ agonists.1. discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem. 41:1998;5020-5036.
178. Shinkai H. The isoxazolidine-3,5-dione agent JTT-501 and other nonthiazolidinedione insulin sensitizers. Drugs Future. 24:1999;893-898.
179. Buckle D.R., Cantello B.C.C., Cawthorne M.A., Coyle P.J., Dean D.K., Faller A., Haigh D., Hindley T.K., Jefcott L.J., Lister C.A., Pinto O.L., Rami H.K., Smith D.G., Smith S.A. Non thiazolidinedione anti-hyperglycemic agents. 1. α-Heteroatom substituted β-phenylpropanoic acids. Bioorg. Med. Chem. Lett. 24:1996;2121-2126.
180. Harrington W.W., Way J., Novak P., Milliken N., Binz J., Smalley T., Collins J., Brown K.K., Kliewer S.A., Willson T.M. Antidiabetic efficacy of GW0072, a selective PPARγ modulator in Zucker Diabetic Fatty rats. 37th Annual Meeting of the European Association for the Study of Diabetes (2001); Glasgow, U.K, A201:2001.
181. 313 in ligand binding. J. Biol. Chem. 274:1999;7913-7922.